Data / Form D filings / Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc.: Form D filings
Oncternal Therapeutics, Inc., a biotechnology company in San Diego, CA, filed 10 Form D notices with the SEC between 2014 and 2018. The latest, on November 21, 2018, reports $17 million sold of a $24 million offering to 1 investor.
Find out what Oncternal Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3525 Del Mar Heights Rd., #821, San Diego, CA, 92130
- Phone
- (858) 434-1113
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2013
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1600987
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 21, 2018 | New notice | $24,000,000 | $17,000,000 | $7,000,000 | 1 | Nov 7, 2018 | sec.gov |
| Sep 27, 2017 | New notice | $11,251,125 | $6,850,397 | $4,400,728 | 121 | Sep 12, 2017 | sec.gov |
| Mar 23, 2017 | Amendment | $23,504,838 | $17,874,045 | $5,630,793 | 111 | Jul 27, 2015 | sec.gov |
| Dec 9, 2016 | Amendment | $20,000,000 | $11,281,734 | $8,718,266 | 95 | Jul 27, 2015 | sec.gov |
| Oct 20, 2016 | Amendment | $20,000,000 | $6,083,738 | $13,916,262 | 72 | Jul 27, 2015 | sec.gov |
| Jul 8, 2016 | New notice | $3,300,000 | $150,000 | $3,150,000 | 3 | Jun 22, 2016 | sec.gov |
| Jun 8, 2016 | New notice | $13,135,714 | $13,135,714 | $0 | 26 | May 27, 2016 | sec.gov |
| Mar 10, 2016 | Amendment | $10,000,000 | $3,709,993 | $6,290,007 | 39 | Jul 27, 2015 | sec.gov |
| Aug 7, 2015 | New notice | $10,000,000 | $3,149,995 | $6,850,005 | 30 | Jul 27, 2015 | sec.gov |
| Mar 5, 2014 | New notice | $3,280,000 | $3,090,000 | $190,000 | 26 | Feb 19, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Richard R. Vincent | Executive Officer | |
| Cam R. Gallagher | Director | |
| Scott L. Glenn | Director | |
| James B. Breitmeyer, M.D., Ph.D. | Executive Officer, Director | |
| Cooper R. Collins | Director | |
| David F. Hale | Director | |
| Charles G. Theuer, M.D. | Director | |
| Lauren G. Otsuki | Executive Officer | |
| William R. LaRue | Director |
Other biotechnology companies in California that filed recently
- CARI Health, Inc. $280,000 · Nov 6, 2026
- Ausel, Inc. $120,000 · Nov 4, 2026
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
- Tempest Therapeutics, Inc. $7.5 million · Oct 14, 2026
- Lionheart Health, Inc. $387,500 · Oct 7, 2026
- Rakuten Medical, Inc. $9 million · Oct 6, 2026
- Zonaliz, Inc. $2.5 million · Oct 5, 2026
- Altay Therapeutics, Inc. $15.7 million · Oct 2, 2026
- Sialia Therapeutics, Inc. $1.5 million · Sep 29, 2026
- Vetmab Biosciences, Inc. $11.4 million · Sep 29, 2026
Every Form D from the week of Nov 19, 2018 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Oncternal Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.